New guidance addresses Australian firms' worries over post-market reviews
This article was originally published in Scrip
A new version of the Australian framework for post-market reviews, which are used to monitor marketed medicines in order to improve the quality of their use and help ensure the sustainability of the Pharmaceutical Benefits Scheme, is expected to be published soon following its adoption by the government and the pharmaceutical industry.
You may also be interested in...
A resolution adopted by the EU’s legislative body includes ways of making Europe more resilient to future pandemics and supply chain risks, and ensuring equitable access to affordable vaccines and medicines. Proposals from the European Parliament to share IP and knowledge have been welcomed by medicines access campaigners.
The need to accelerate clinical trials of products for treating and preventing coronavirus has led the EU authorities to propose a more streamlined process for allowing the release of GMO-containing investigational medicinal products into the environment.
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.